A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma

被引：3

作者：

Ott, P. A. ^{[1
,2
]}

Pavlick, A. C. ^{[3
]}

Johnson, D. B. ^{[4
]}

Hart, L. L. ^{[5
]}

Infante, J. R. ^{[6
]}

Luke, J. J. ^{[7
]}

Lutzky, J. ^{[8
]}

Rothschild, N. ^{[9
]}

Spitler, L. ^{[10
]}

Cowey, C. L. ^{[11
]}

Alizadeh, A. ^{[12
]}

Salama, A. ^{[13
]}

He, Y. ^{[14
]}

Bagley, R. G. ^{[15
]}

Zhang, J. ^{[15
]}

Hamid, O. ^{[16
]}

机构：

[1] Dana Farber Canc Inst, Melanoma Ctr, Boston, MA 02115 USA

[2] Dana Farber Canc Inst, Ctr Immunooncol, Boston, MA 02115 USA

[3] NYU, Sch Med, Dept Med, New York, NY USA

[4] Vanderbilt Ingram Canc Ctr, Dept Med, Nashville, TN USA

[5] Florida Canc Specialists, Hematol Oncol, Ft Myers, FL USA

[6] Tennessee Oncol PLLC, Dept Med, Nashville, TN USA

[7] Univ Chicago, Hematol Oncol, Chicago, IL 60637 USA

[8] Mt Sinai Comprehens Canc Ctr, Div Hematol Oncol, Dept Med, Miami Beach, FL USA

[9] Florida Canc Specialists, Dept Med, W Palm Beach, FL USA

[10] St Marys Hosp, Northern Calif Melanoma Ctr, San Francisco, CA USA

[11] Baylor Univ, Med Ctr, Baylor Skin Malignancy & Treatment Ctr, Dallas, TX USA

[12] Georgia Canc Specialists, Cent Res, Decatur, GA USA

[13] Duke Univ, Dept Med, Durham, NC USA

[14] Celldex Therapeut Inc, Biostat, Hampton, NJ USA

[15] Celldex Therapeut Inc, Clin Sci, Hampton, NJ USA

[16] Angeles Clin & Res Inst, Dept Translat Res ImmunoOncol, Los Angeles, CA USA

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw379.42

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1147P

引用

页数：1

共 50 条

[1] A phase II study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma
Ott, Patrick Alexander
Pavlick, Anna C.
Johnson, Douglas Buckner
Hart, Lowell L.
Infante, Jeffrey R.
Luke, Jason John
Lutzky, Jose
Rothschild, Neal Evan
Spitler, Lynn E.
Cowey, Charles Lance
Alizadeh, Aaron
Salama, April K.
Yin, Xiaoyan
Bagley, Rebecca G.
Wang, Ying
Hamid, Omid
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[2] Glembatumumab vedotin (GV), an anti-gpNMB antibody-drug conjugate (ADC), in combination with varlilumab (V), an anti-CD27 antibody, in advanced melanoma
Hamid, Omid
Pavlick, Anna C.
Cowey, C. Lance
Hart, Lowell
Johnson, Douglas B.
Lutzky, Jose
Alizadeh, Aaron
Spigel, David
Rothschild, Neal
Salama, April
Weber, Robert
Luke, Jason J.
Wang, Ying
Yellin, Michael
He, Yi
Bagley, Rebecca G.
Ott, Patrick
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
[3] A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma
Ott, Patrick A.
Pavlick, Anna C.
Johnson, Douglas B.
Hart, Lowell L.
Infante, Jeffrey R.
Luke, Jason J.
Lutzky, Jose
Rothschild, Neal E.
Spitler, Lynn E.
Cowey, C. Lance
Alizadeh, Aaron R.
Salama, April K.
He, Yi
Hawthorne, Thomas R.
Bagley, Rebecca G.
Zhang, Joshua
Turner, Christopher D.
Hamid, Omid
CANCER, 2019, 125 (07) : 1113 - 1123
[4] Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma
Ott, Patrick A.
Hamid, Omid
Pavlick, Anna C.
Kluger, Harriet
Kim, Kevin B.
Boasberg, Peter D.
Simantov, Ronit
Crowley, Elizabeth
Green, Jennifer A.
Hawthorne, Thomas
Davis, Thomas A.
Sznol, Mario
Hwu, Patrick
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (32) : 3659 - +
[5] METRIC: A randomized international phase 2b study of the antibody-drug conjugate (ADC) glembatumumab vedotin (GV) in gpNMB-overexpressing, metastatic, triple-negative breast cancer (mTNBC)
Vahdat, L. T.
Forero-Torres, A.
Schmid, P.
Blackwell, K.
Telli, M. L.
Melisko, M.
Holgado, E.
Moebus, V.
Cortes, J.
Fehrenbacher, L.
Montero, A. J.
Ma, C.
Nanda, R.
Wright, G. S.
He, Y.
Bagley, R. G.
Halim, A.
Turner, C. D.
Yardley, D. A.
CANCER RESEARCH, 2019, 79 (04)
[6] Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma
Roth, Michael
Barris, David M.
Piperdi, Sajida
Kuo, Vicky
Everts, Stephanie
Geller, David
Houghton, Peter
Kolb, E. Anders
Hawthorne, Thomas
Gill, Jonathan
Gorlick, Richard
PEDIATRIC BLOOD & CANCER, 2016, 63 (01) : 32 - 38
[7] Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Locally Advanced or Metastatic Breast Cancer
Bendell, Johanna
Saleh, Mansoor
Rose, April A. N.
Siegel, Peter M.
Hart, Lowell
Sirpal, Surendra
Jones, Suzanne
Green, Jennifer
Crowley, Elizabeth
Simantov, Ronit
Keler, Tibor
Davis, Thomas
Vahdat, Linda
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (32) : 3619 - +
[8] A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate (ADC) targeting glycoprotein NMB (GPNMB) in patients (pts) with advanced melanoma
Hwu, P.
Sznol, M.
Pavlick, A.
Kluger, H.
Kim, K. B.
Boasberg, P.
Sanders, D.
Simantov, R.
Crowley, E.
Hamid, O.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[9] B-raf/Mek/Erk Pathway inhibition induces GPNMB expression and sensitizes melanoma cells to the antibody-drug conjugate glembatumumab vedotin
Rose, April A. N.
Siegel, Peter M.
MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
[10] Phase I/II Study of CR011-vcMMAE, an Antibody-drug Conjugate Targeting GPNMB, for the Treatment of Patients With Advanced Melanoma
Hwu, Patrick
Sznol, M.
Pavlick, A.
Kluger, H.
Kim, K. B.
Hwu, W. J.
Papadopoulos, N.
Sanders, D.
Boasberg, P.
Simantov, R.
Hamid, O.
JOURNAL OF IMMUNOTHERAPY, 2008, 31 (09) : 970 - 971

← 1 2 3 4 5 →